Advances in the treatment of prostate cancer - PubMed (original) (raw)

Review

Advances in the treatment of prostate cancer

Mark Pomerantz et al. Annu Rev Med. 2007.

Abstract

Several recent advances have been made in the management of prostate cancer. Active surveillance is an increasingly attractive and reasonable approach for those with low-volume, low-risk disease. For locally advanced or localized high-risk disease, neoadjuvant and adjuvant therapies are emerging as the standard of care. Innovative uses of traditional hormonal treatments can potentially limit common side effects. Recent data also support the utility of second-line hormonal therapy. For the first time, a survival advantage with the use of chemotherapy has been established. Much work is under way to augment its efficacy with novel agents such as targeted therapeutics and tumor vaccines. Recent scientific breakthroughs suggest additional strategies in treating prostate cancer.

PubMed Disclaimer

Similar articles

• [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
  Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. Mottet N, et al. Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Actas Urol Esp. 2011. PMID: 21757258 Spanish.
• Endocrine treatment of prostate cancer.
  Tammela T. Tammela T. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review.
• [Keyrole of endocrinology in the victory against prostate cancer].
  Labrie F. Labrie F. Bull Cancer. 2006 Sep;93(9):949-58. Bull Cancer. 2006. PMID: 16980238 Review. French.
• Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
  Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators. Kawakami J, et al. Cancer. 2006 Apr 15;106(8):1708-14. doi: 10.1002/cncr.21799. Cancer. 2006. PMID: 16544313
• [First line therapy in the treatment of metastatic prostate cancer].
  Sakai H, Kanetake H. Sakai H, et al. Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Gan To Kagaku Ryoho. 2003. PMID: 12557704 Review. Japanese.

Cited by

• MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
  Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D. Qi W, et al. BMC Cancer. 2009 May 11;9:142. doi: 10.1186/1471-2407-9-142. BMC Cancer. 2009. PMID: 19432987 Free PMC article.
• Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.
  Northup JR, Deutscher SL. Northup JR, et al. Comb Chem High Throughput Screen. 2016;19(5):370-7. doi: 10.2174/1386207319666160408151423. Comb Chem High Throughput Screen. 2016. PMID: 27055748 Free PMC article.
• The RelB alternative NF-kappaB subunit promotes autophagy in 22Rv1 prostate cancer cells in vitro and affects mouse xenograft tumor growth in vivo.
  Labouba I, Poisson A, Lafontaine J, Delvoye N, Gannon PO, Le Page C, Saad F, Mes-Masson AM. Labouba I, et al. Cancer Cell Int. 2014 Jul 28;14:67. doi: 10.1186/1475-2867-14-67. eCollection 2014. Cancer Cell Int. 2014. PMID: 25788857 Free PMC article.
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
  Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Scher HI, et al. Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14. Lancet. 2010. PMID: 20398925 Free PMC article. Clinical Trial.
• Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.
  Jayanna PK, Bedi D, Gillespie JW, DeInnocentes P, Wang T, Torchilin VP, Bird RC, Petrenko VA. Jayanna PK, et al. Nanomedicine. 2010 Aug;6(4):538-46. doi: 10.1016/j.nano.2010.01.005. Epub 2010 Feb 4. Nanomedicine. 2010. PMID: 20138246 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc

• Medical

  • MedlinePlus Health Information